XVIII CONGRESSO NAZIONALE AIOM - ROMA, October 28th-30th 2016

Leonid’s product and impacts

• RealQuant® Lung Fusion Genes, medical device validated for in vitro diagnostic use under the 98/79/EC directive.
• One test for multiple biomarkers detection and quantification (ALK, ROS1 and RET gene rearrangements in the same reaction) --> reduction of costs.
• Identification of the main fusion genes in the same well.
• Standardized results without personal interpretation and simplification of the medical report thanks to a dedicated software for secondary analysis on Nanostring® output data --> reduction of data decoding errors.
• Easy-of-use (only 4 pipetting steps) --> reduction of hands-on-time and manual errors. 
• Higher throughput (up to 10 samples per run).
• Faster workflow (from FFPE tissue to data in less than 2 days).
• Quality control of pre-analytical and analytical steps.
• Performance validated in a multicenter clinical study at Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell'Area Critica, Università di Pisa - Azienda Ospedaliero Universitaria Pisana (Pisa) and at Laboratorio di Bioscienze, Diagnostica Molecolare di III livello - Biomarcatori e Medicina Personalizzata, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) IRCCS (Meldola). 

Horizon 2020 programma quadro in ricerca e innovazione: le varie opportunità per la salute, cenni alla progettazione e confronto tra le esperienze pubblico - private  

Rome 14th July Ministry of Health Auditorium, Viale Giorgio Ribotta 5, Rome

Maura Menghi Diatech Pharmacogenetics Scientific Directors and IRCSS Meldola Staff take part in session number 3:

Esperienze vincenti in Horizon 2020: il valore della collaborazione tra pubblico e privato

• Fabrizia Lattanzio, INRCA, Progetto Scop

• Marina Cuttini, Ospedale Pediatrico Bambino Gesù, SHIPS

• Marco Molinari, Fondazione Santa Lucia, Progetto NISCI

• Costantino Bongiorno, WeMake, Progetto Opencare

• Evert Jan Hoogerwerf, AIAS, Progetto ProACT (contributo video)

• Maura Menghi, Diatech Pharmacogenetics, Progetto LEONID

• Michele Nicoletta, ABBVIE

• Sigma-tau (tbc)    

Press Review "Terapie su Misura" Business People

Horizon 2020: i nuovi bandi 2016-17 (NMBP)

Confindustria Ancona 21st October 2015

All’interno del ciclo di incontri “R&I: Diamo credito alla ricerca”, il Desk Europa di Confindustria Ancona propone, in collaborazione con l'Agenzia Per la Ricerca Europea (APRE), un incontro sui nuovi bandi 2016-2017 del programma europeo per la ricerca e l'innovazione, Horizon2020, sulla tematica relativa a nanotecnologie, materiali avanzati, biotecnologie, manifatturiero avanzato e processi (NMBP).


Program:

15:30 Registration

16:00 Greetings
Claudio Schiavoni, President of Confindustria Ancona

16:10 Presentation of the first results of Horizon 2020
Elisabetta Giromini, Desk Europe di Confindustria Ancona

16:25 Presentation of new work programs and for the telematics NMBP
Serena Borgna, APRE

17:10 Testimony winning company PMI Instrument Phase 2
Oliva Alberti, AD Diatech Pharmacogenetics17:30 Practical advice by an evaluator of projects Horizon2020

Cristina Cristalli, Head R&D Loccioni

17:50 Q&A

For more information please contact: Elisabetta Giromini, Tel.: +39 071 29048225;

Giornata nazionale di lancio dei bandi 2016-17 Horizon 2020

 6th October 2015, Sapienza University, Aula Magna, Piazzale Aldo Moro, 5 Rome

Oliva Alberti, CEO Diatech Pharmacogenetics participated as a speaker  during the section 2:

"Sessione 2 “Tavola rotonda sulle esperienze di coordinamento e di valutazione nei ban- di “health, demographic change and well-being, 2014-2015” (14:30 – 16:30)"

Download here the complete presentation.

Horizon 2020 Project LEONID Lung cancEr fusiOn geNes: a new dIagnostic Device

The main scope of LEONID project is the development and validation of the clinical performance of a new diagnostic Nanostring-based device against existing standards (FISH and IHC) for the detection of in vitro biomarkers with predictive power of response to tyrosin kinase inhibitors used for lung cancer treatment.
The device will be the first CE-IVD kit that detects all ALK, ROS1 and RET rearrangements with known and unknown partners in one multiplex assay and that, at the same time, identify the main variants of EML4-ALK.
The clinical validation will be extended to the associated software for secondary analysis of data that will guarantee the results standardization, avoiding any personal interpretation. The new diagnostic device-software combination, that passed the technical feasibility analysis and is ready for experimental verification, will be the easiest, cheapest, fastest and standardized solution for ALK, ROS1 and RET fusions detection without losing sensitivity, specificity, robustness and reproducibility.
The end users will be all molecular pathology laboratories supporting hospitals where lung cancer patients are treated, that (are going to) perform the analysis of fusion genes and want to reduce hands-on-time, error rate, and costs, saving specialized technical expertise and increasing the throughput of biomarkers and samples. At least 85 European medium-high throughput labs running 450 lung samples per year can be considered as potential customers.
For Diatech Pharmacogenetics, the new device will be complementary to the existing products for pharmacogenetics analysis in oncology and will boost the company’s approach of potential European distributors. GeneticLab can offer the test to low throughput labs and can speed up the entrance into the oncology business. BiMind can extend the panel of features of its proprietary oncology EHR dedicated to the analysis of laboratory tests’ results and can provide its new software through Diatech PGx or directly.

Project reference: 673953